CJC-1295 med DAC
Long-acting albumin-binding GHRH analogue. Human studies report a 5.8–8.1 day half-life.
Search names: CJC-1295 with DAC, CD
Evidence
Human · pharmacokinetics
Describes the linked sources, not an overall score for product quality or effectiveness.Half-life
5.8–8.1 days in the linked human study. Applies to the long-acting DAC variant.
Statistics reference: 5.8–8.1 days
Human information in catalogueContext and sources for the statistics reference
Applies to the DAC variant; must not be used for CJC-1295 without DAC.
5.8–8.1 days · Catalogue information from PeptideTracker.ai; read the limitation above. PeptideTracker.ai · CJC-1295 (DAC) ↗
Half-life, duration of effect and shelf life are different measures. Catalogue values may differ between variants and administration routes. Curves continue to use their stated statistics reference.
Adverse effects and limitations
The regulatory source below describes safety concerns or data gaps. Administration route and product identity matter.
Sources and further reading
Vital · user-supplied screen recordings, 1 Nov 2026
Study / medicine dataCJC-1295 · human pharmacokinetic trial↗Regulatory sourceFDA · substance-specific safety information↗Find researchPubMed · CJC-1295 med DAC↗Research information, not a personal dosing plan. Last reviewed: 2026-11-01.